{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:05:57Z","timestamp":1782774357036,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40272-022-00553-8","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T01:02:35Z","timestamp":1671411755000},"page":"67-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine C.","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-8722","authenticated-orcid":false,"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7411-5375","authenticated-orcid":false,"given":"Peter D.","family":"Arkwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8346-8298","authenticated-orcid":false,"given":"Mercedes E.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lockshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-5121","authenticated-orcid":false,"given":"Noah A.","family":"Levit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7672-5460","authenticated-orcid":false,"given":"Randy","family":"Prescilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"issue":"1","key":"553_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. https:\/\/doi.org\/10.1038\/s41572-018-0001-z.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"553_CR2","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","volume":"5","author":"M Boguniewicz","year":"2017","unstructured":"Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519\u201331. https:\/\/doi.org\/10.1016\/j.jaip.2017.08.005.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"553_CR3","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjd.15928","volume":"178","author":"AM Drucker","year":"2018","unstructured":"Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768\u201375. https:\/\/doi.org\/10.1111\/bjd.15928.","journal-title":"Br J Dermatol"},{"issue":"6","key":"553_CR4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378. https:\/\/doi.org\/10.1111\/jdv.14888.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"14","key":"553_CR5","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111(14):5147\u201352. https:\/\/doi.org\/10.1073\/pnas.1323896111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"553_CR6","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111(14):5153\u20138. https:\/\/doi.org\/10.1073\/pnas.1324022111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"553_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350. https:\/\/doi.org\/10.1038\/nrd4624.","journal-title":"Nat Rev Drug Discov"},{"issue":"10086","key":"553_CR8","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"5","key":"553_CR9","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178(5):1083\u2013101. https:\/\/doi.org\/10.1111\/bjd.16156.","journal-title":"Br J Dermatol"},{"issue":"5","key":"553_CR10","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054.","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"553_CR11","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"1","key":"553_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"553_CR13","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182(5):1120\u201335. https:\/\/doi.org\/10.1111\/bjd.18434.","journal-title":"Br J Dermatol"},{"issue":"2","key":"553_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40257-020-00583-3","volume":"22","author":"EC Siegfried","year":"2021","unstructured":"Siegfried EC, Bieber T, Simpson EL, Paller AS, Beck LA, Boguniewicz M, et al. Effect of dupilumab on laboratory parameters in adolescents with atopic dermatitis: results from a randomized, placebo-controlled, phase 3 clinical trial. Am J Clin Dermatol. 2021;22(2):243\u201355. https:\/\/doi.org\/10.1007\/s40257-020-00583-3.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"553_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40272-021-00459-x","volume":"23","author":"AS Paller","year":"2021","unstructured":"Paller AS, Wollenberg A, Siegfried E, Tha\u00e7i D, Cork MJ, Arkwright PD, et al. Laboratory safety of dupilumab in patients aged 6\u201311 years with severe atopic dermatitis: results from a phase III clinical trial. Pediatr Drugs. 2021;23(5):515\u201327. https:\/\/doi.org\/10.1007\/s40272-021-00459-x.","journal-title":"Paediatr Drugs"},{"issue":"6","key":"553_CR16","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/cpt.1058","volume":"104","author":"JD Davis","year":"2018","unstructured":"Davis JD, Bansal A, Hassman D, Akinlade B, Li M, Li Z, et al. Evaluation of potential disease-mediated drug-drug interaction in patients with moderate-to-severe atopic dermatitis receiving dupilumab. Clin Pharmacol Ther. 2018;104(6):1146\u201354. https:\/\/doi.org\/10.1002\/cpt.1058.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"553_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","volume":"23","author":"LA Beck","year":"2022","unstructured":"Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393\u2013408. https:\/\/doi.org\/10.1007\/s40257-022-00685-0.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"553_CR18","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1080\/09546634.2020.1871463","volume":"33","author":"LA Beck","year":"2022","unstructured":"Beck LA, Tha\u00e7i D, Deleuran M, de Bruin-Weller M, Chen Z, Khokhar FA, et al. Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. J Dermatolog Treat. 2022;33(3):1608\u201316. https:\/\/doi.org\/10.1080\/09546634.2020.1871463.","journal-title":"J Dermatolog Treat"},{"issue":"10356","key":"553_CR19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2.","journal-title":"Lancet"},{"issue":"4","key":"553_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2332\/allergolint.O-08-537","volume":"57","author":"R Tamagawa-Mineoka","year":"2008","unstructured":"Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Elevated platelet activation in patients with atopic dermatitis and psoriasis: increased plasma levels of beta-thromboglobulin and platelet factor 4. Allergol Int. 2008;57(4):391\u20136. https:\/\/doi.org\/10.2332\/allergolint.O-08-537.","journal-title":"Allergol Int"},{"issue":"2","key":"553_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jdermsci.2008.08.019","volume":"53","author":"N Katoh","year":"2009","unstructured":"Katoh N. Platelets as versatile regulators of cutaneous inflammation. J Dermatol Sci. 2009;53(2):89\u201395. https:\/\/doi.org\/10.1016\/j.jdermsci.2008.08.019.","journal-title":"J Dermatol Sci"},{"issue":"4","key":"553_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1365-2230.1990.tb02086.x","volume":"15","author":"M Uehara","year":"1990","unstructured":"Uehara M, Izukura R, Sawai T. Blood eosinophilia in atopic dermatitis. Clin Exp Dermatol. 1990;15(4):264\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1990.tb02086.x.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"553_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000247419","volume":"185","author":"MK K\u00e4gi","year":"1992","unstructured":"K\u00e4gi MK, Joller-Jemelka H, W\u00fcthrich B. Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. Dermatology. 1992;185(2):88\u201392. https:\/\/doi.org\/10.1159\/000247419.","journal-title":"Dermatology"},{"issue":"5","key":"553_CR24","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc'h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204. https:\/\/doi.org\/10.1111\/all.14151.","journal-title":"Allergy"},{"key":"553_CR25","first-page":"A5555","volume":"199","author":"J Allinne","year":"2019","unstructured":"Allinne J, Scott G, Birchard D, Asrat S, Nagashima K, Le Floc\u2019h A, et al. Broader impact of IL-4R\u03b1 blockade than IL-5 blockade on mediators of type 2 inflammation and lung pathology in a house dust mite-induced asthma mouse model. Am J Respir Crit Care Med. 2019;199:A5555.","journal-title":"Am J Respir Crit Care Med"},{"key":"553_CR26","first-page":"PA577","volume":"52","author":"JM Orengo","year":"2018","unstructured":"Orengo JM, Allinne J, Le Floc\u2019h A, Potocky T, Kim JH, Birchard D, et al. Blocking IL-4Ra with dupilumab prevents lung inflammation in a mouse asthma model. Eur Respir J. 2018;52:PA577.","journal-title":"Eur Respir J"},{"issue":"26","key":"553_CR27","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1804092.","journal-title":"N Engl J Med"},{"issue":"26","key":"553_CR28","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa1804093.","journal-title":"N Engl J Med"},{"issue":"10209","key":"553_CR29","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1.","journal-title":"Lancet"},{"issue":"10","key":"553_CR30","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695\u2013709. https:\/\/doi.org\/10.1016\/j.jaip.2022.05.019.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"553_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11899-018-0448-8","volume":"13","author":"MC Dispenza","year":"2018","unstructured":"Dispenza MC, Bochner BS. Diagnosis and novel approaches to the treatment of hypereosinophilic syndromes. Curr Hematol Malig Rep. 2018;13(3):191\u2013201. https:\/\/doi.org\/10.1007\/s11899-018-0448-8.","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"553_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11882-012-0241-z","volume":"12","author":"SG Pl\u00f6tz","year":"2012","unstructured":"Pl\u00f6tz SG, H\u00fcttig B, Aigner B, Merkel C, Brockow K, Akdis C, et al. Clinical overview of cutaneous features in hypereosinophilic syndrome. Curr Allergy Asthma Rep. 2012;12(2):85\u201398. https:\/\/doi.org\/10.1007\/s11882-012-0241-z.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"553_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.iac.2016.08.008","volume":"37","author":"JL Thijs","year":"2017","unstructured":"Thijs JL, de Bruin-Weller MS, Hijnen D. Current and future biomarkers in atopic dermatitis. Immunol Allergy Clin N Am. 2017;37(1):51\u201361. https:\/\/doi.org\/10.1016\/j.iac.2016.08.008.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"10","key":"553_CR34","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.jid.2018.03.1517","volume":"138","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Villarreal M, Jepson B, Rafaels N, David G, Hanifin J, et al. Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype. J Invest Dermatol. 2018;138(10):2224\u201333. https:\/\/doi.org\/10.1016\/j.jid.2018.03.1517.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"553_CR35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1346-8138.1990.tb01679.x","volume":"17","author":"H Mukai","year":"1990","unstructured":"Mukai H, Noguchi T, Kamimura K, Nishioka K, Nishiyama S. Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis. J Dermatol. 1990;17(8):477\u201381. https:\/\/doi.org\/10.1111\/j.1346-8138.1990.tb01679.x.","journal-title":"J Dermatol"},{"issue":"4","key":"553_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00403-011-1198-9","volume":"304","author":"K Kou","year":"2012","unstructured":"Kou K, Aihara M, Matsunaga T, Chen H, Taguri M, Morita S, et al. Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis. Arch Dermatol Res. 2012;304(4):305\u201312. https:\/\/doi.org\/10.1007\/s00403-011-1198-9.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"553_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4274\/jcrpe.v3i1.02","volume":"3","author":"S Turan","year":"2011","unstructured":"Turan S, Topcu B, G\u00f6k\u00e7e \u0130, G\u00fcran T, Atay Z, Omar A, et al. Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets. J Clin Res Pediatr Endocrinol. 2011;3(1):7\u201311. https:\/\/doi.org\/10.4274\/jcrpe.v3i1.02.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"4","key":"553_CR38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamadermatol.2014.3432","volume":"151","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI, Paller AS. Association between eczema and stature in 9 US population-based studies. JAMA Dermatol. 2015;151(4):401\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2014.3432.","journal-title":"JAMA Dermatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00553-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00553-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00553-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T15:31:57Z","timestamp":1677684717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00553-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00553-8","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"6 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A peer-reviewed video abstract was retrospectively added to this publication.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT03346434, part B. The study sponsors participated in the study design; collection, analysis, and interpretation of the data; writing of the report; and the decision to submit the article for publication. The study sponsors\u00a0paid the open access fee.\u00a0The National Institute for Health and Care Research provided support to The Manchester Clinical Research Facility at Royal Manchester Children\u2019s Hospital in Manchester, UK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.S.P. reports being an investigator for AbbVie, Eli Lilly, Incyte, and Regeneron Pharmaceuticals, Inc.; a consultant with honorarium for AbbVie, Almirall, Arcutis Biotherapeutics, Arena Pharmaceuticals, BiomX, Bristol Myers Squibb, Catawba Research, Eli Lilly, Galderma, Gilead, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi, and Seanergy; and on a data safety monitoring board for Bausch Health and Galderma. E.C.S. reports being a consultant for AbbVie, Amgen, Eli Lilly, Gilead, Incyte, Novan, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi, and Verrica Pharmaceuticals; on a data and safety monitoring board for LEO Pharma, Novan, Pfizer, and UCB; and a Principal Investigator in clinical trials for Eli Lilly, Janssen, Regeneron Pharmaceuticals, Inc., and Verrica Pharmaceuticals. M.J.C. reports being an investigator and\/or consultant for AbbVie, Astellas Pharma, Boots, Dermavant, Galapagos, Galderma, Hyphens Pharma, Johnson & Johnson, LEO Pharma, L\u2019Or\u00e9al, Menlo Therapeutics, Novartis, Oxagen, Pfizer, Procter & Gamble, Reckitt Benckiser, Regeneron Pharmaceuticals, Inc., and Sanofi. A.W. reports being an investigator for Beiersdorf, Eli Lilly, Galderma, LEO Pharma, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi; a consultant for AbbVie, Aileens Pharma, Almirall, Anacor Pharmaceuticals, Eli Lilly, Galapagos, Galderma, GSK, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi; and receiving research grants (to the institution) from Beiersdorf, LEO Pharma, and Pierre Fabre. P.D.A. reports being an investigator for Regeneron Pharmaceuticals, Inc.; and receiving a research grant from, and being an advisor for Sanofi. M.E.G. reports being an investigator for AbbVie, Arcutis Biotherapeutics, Dermira, Dermavant, Eli Lilly, Incyte, Krystal Biotech, Regeneron Pharmaceuticals, Inc., Sun Pharma, and Verrica Pharmaceuticals; a speaker for Galderma, Pfizer, Primus Pharmaceuticals, Regeneron Pharmaceuticals, Inc., and Sanofi; and a consultant for Noble Pharma, Unilever, and Verrica Pharmaceuticals. B.L. reports being an investigator\u00a0and a speaker for Eli Lilly and Regeneron Pharmaceuticals, Inc.; an investigator for Anacor Pharmaceuticals, Dermira, Franklin Bioscience, and LEO Pharma; an investigator, speaker, and consultant for AbbVie; and a speaker, consultant, and researcher for Incyte. Z.C., A.B., and N.A.L. are employees and shareholders of Regeneron Pharmaceuticals, Inc. R.P. is an employee of Sanofi and may hold stock and\/or stock options in the company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The study was conducted following the ethical principles derived from the Declaration of Helsinki, the International Council for Harmonisation guidelines, Good Clinical Practice, and local applicable regulatory requirements. Local institutional review boards or ethics committees at each trial center oversaw trial conduct and documentation and reviewed and approved the study protocol. A full list of investigators and their affiliations are provided in Reference 19 (Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908\u201319. ).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the patients\u2019 parents\/guardians prior to the start of any study treatment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this article. Individual anonymized participant data will be considered for sharing once the product and indication has been approved by major health authorities (e.g., US Food and Drug Administration, European Medicines Agency, Pharmaceuticals and Medical Devices Agency), if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ASP, ECS, MJC, AW, PDA, MEG, and BL acquired the data. ZC conducted the statistical analyses on the data. All authors interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}